血液・幹細胞移植科 論文(2022年)
| 【英語論文】 | ||
| 1. Yasui K, Enami T, Okamura-Shiki I, Ueda T, Fukushima K, Matsuyama N, Kimura T, Takanashi M, Hosen N, Ikeda T, Takihara Y and Hirayama F; Passive immune basophil activation test for the identification of allergic episodes from various adverse events elicited by haematopoietic cell transplantation: A pilot study. Vox Sang, 117, 119-127, 2022 | ||
| 2. Iida S, Izumi T, Komeno T, Terui Y, Chou T, Ikeda T, Berg D, Fukunaga S, Sugiura K and Sasaki M; A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. International Journal of Clinical Oncology, 27, 224-233, 2022. | ||
| 3. Imahashi N, Terakura S, Kondo E, Kato K, Kim SW, Shinohara A, Watanabe M, Fukuda T, Uchida N, Kobayashi H, Ishikawa J, Kataoka K, Shiratori S, Ikeda T, Matsuoka KI, Yoshida S, Kondo T, Kimura T, Onizuka M, Ichinohe T, Atsuta Y and Kanda J; Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplantation, 57, 243-251, 2022 | ||
| 4. Akahoshi Y, Kimura S, Tada Y, Matsukawa T, Tamaki M, Doki N, Uchida N, Tanaka M, Nakamae H, Kuriyama T, Matsuoka K, Ikeda T, Kimura T, Fukuda T, Kanda Y, Atsuta Y, Murata M, Terakura S and Nakasone H; Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. Blood Advances, 6, 574-584, 2022 | ||
| 5. Kume T, Shimizu R, Akiyama K, Tsuchiya T, Shino M, Ikeda T and Iwai S; Hand-foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients. Support Care Cancer, 30, 1539-1546, 2022 | ||
| 6. Wada F, Kanda J, Yoshioka S, Ishikawa T, Akasaka T, Ueda Y, Hirata H, Arai Y, Yago K, Anzai N, Watanabe M, Ikeda T, Yonezawa A, Imada K, Itoh M, Kitano T, Takeoka T, Hishizawa M, Nohgawa M, Arima N, Asagoe K, Kondo T and Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Single cord blood transplantation versus HLA-haploidentical-related donor transplantation using posttransplant cyclophosphamide in patients with hematological malignancies. Transplantation, 106, 1279-1287, 2022 | ||
| 7. Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y and Kondo E; Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia, 36, 1361-1370, 2022 | ||
| 8. Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S and Kondo E; An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. International Journal of Hematology, 115, 391-398, 2022 | ||
| 9. Okamura-Shiki I, Asakura K and Ikeda T; Neurolymphomatosis as a manifestation of relapsed diffuse large B-cell lymphoma. EJHaem, 3, 1396-1397, 2022 | ||
| 10. Sunami K, Ikeda T, Huang SY, Wang MC, Koh Y, Min CK, Yeh SP, Matsumoto M, Uchiyama M, Iyama S, Shimazaki C, Lee JH, Kim K, Kaneko H, Kim JS, Lin TL, Campana F, Tada K, Iida S and Suzuki K; ICARIA-MM study group; Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup | ||
| Analysis. Clinical Lymphoma Myeloma Leukemia, 22, e751-761, 2022 11. Sakatoku K, Kim SW, Okamura H, Kanaya M, Kato K, Yamasaki S, Uchida N, Kobayashi H, Fukuda T, Takayama N, Ishikawa J, Nakazawa H, Sakurai M, Ikeda T, Kondo T, Yoshioka S, Miyamoto T, Kimura T, Ichinohe T, Atsuta Y and Kondo E; Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. Annals of Haematology, 101, 2743-2757, 2022 |
||
| 12. Aoyama T, Imataki O, Notsu A, Yurikusa T, Ichimaru K, Tsuji M, Yoshitsugu K, Fukaya M, Enami T and Ikeda T; Examination of a nutritional treatment pathway according to pretreatment health status and stress levels of patients undergoing hematopoietic stem cell transplantation. PLoS One, 17, e0271728, 2022. | ||
| 13. Aoyama T, Notsu A, Ichimaru K, Hayashi K, Tsuji M, Yoshitsugu K, Fukaya M, Enami T and Ikeda T; Impact of body mass index on 5-year survival rates in patients undergoing allogeneic hematopoietic stem cell transplantation. Nutrition and Metabolic Insights. 2022 Oct 7; 15: 11786388221128362. doi: 10.1177/11786388221128362. | ||
| 14. Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K and Iida S; Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study. Hematological Oncology, 2022 Nov 26. doi: 10.1002/hon.3105. Online ahead of print. | ||